By federal statute, Medicare Part D (including Part D coverage inside Medicare Advantage) excludes drugs used for weight loss. One exception is the Medicare GLP-1 Bridge, a CMS demonstration running from July 1, 2026 to December 31, 2027: eligible Part D members pay a flat $50/month for Wegovy (pen or pill), Zepbound KwikPen or Foundayo. It runs outside your plan’s regular benefit, so your plan does not have to opt in, and the $50 does not count toward your deductible or out-of-pocket cap. Separately, Part D can cover a GLP-1 for a covered indication: Ozempic and Mounjaro for type 2 diabetes, Zepbound for obstructive sleep apnea, or Wegovy for cardiovascular risk reduction in eligible patients — when your plan’s formulary lists it, usually with prior authorization.
If none of these applies, Lilly’s Zepbound self-pay ($299–$699/month) is a cash price open to Medicare members, while Novo Nordisk’s terms bar government-plan members from its Ozempic offers even as cash. Confirm your specific plan’s current-year formulary.